<DOC>
	<DOCNO>NCT01364623</DOCNO>
	<brief_summary>The purpose study assess bioavailability total testosterone pharmacokinetic profile obtain follow ( ) single administration three dose TBS-2 b ) multiple administration TBS-2 . In addition , assess bioavailability free testosterone , dihydrotestosterone , SHBG estradiol pharmacokinetic profile also conduct .</brief_summary>
	<brief_title>PK Study Testosterone Nasal Gel ( TBS-2 ) Healthy Premenopausal Women</brief_title>
	<detailed_description>This 2 Period study require overnight stay clinic . Blood sample require visit include sample predefined time period overnight stay . Period I Subjects checked-in Day 1 Period I start baseline testosterone measurement ( dependant menstrual cycle , preferably within 48hr start menstrual cycle ) . They remain institutionalized Day 4 morning , check 48 hour blood draw study close-out continue Period II . Period II ( Multi-Dose ) Subjects institutionalized start Day 1 Visit 3 Day 5 morning Visit 3 , check 48 hour blood draw study close-out .</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria Subjects regular menstrual cycle 2632 day . Women childbearing potential must agree use one follow reliable birth control method prior study , study one month end study : Surgically sterile Intrauterine device place least 3 month prior study initiation Barrier method ( condom spermicidal agent use partner ) Abstinence Negative drug abuse , hepatitis Bsurface antigen , hepatitis C , HIV , pregnancy ( serum ßHCG ) . Body Mass Index great equal 18.5 kg/m² less equal 35 kg/m² . Subjects normal ENT exam . Subjects normal TSH value . No clinically significant finding physical examination , 12lead ECG vital sign Normal thyroid function . Physiological prolactin concentration . All clinical laboratory test value within acceptable range ( clinically significant finding require investigator/sponsor approval ) Able understand provide write informed consent . Availability subject entire study period willingness subject adhere protocol requirement , evidence sign ICF Exclusion Criteria Known history hypersensitivity Testosterone ( e.g . Intrinsa patch ) and/or relate drug . Known history polycystic ovarian syndrome . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , psychiatric , hematological , reproductive , liver kidney disease , unless judge clinically significant Principal Investigator medical designate . Presence known history Estrogenresponsive tumor breast cancer /or history cancer , exclude basal cell carcinoma . Known history frequent clinically significant acne . Known history hirsutism History nasal surgery , specifically turbinoplasty , septoplasty , rhinoplasty , `` nose job '' , sinus surgery . Prior nasal fracture . Active allergy , rhinitis , rhinorrhea , nasal congestion . Mucosal inflammatory disorder , specifically pemphigus , Sjogren 's syndrome . Sinus disease , specifically acute sinusitis , chronic sinusitis , allergic fungal sinusitis . History nasal disorder sleep apnea . Use form intranasal medication delivery , specifically nasal corticosteroid oxymetazoline contain nasal spray History Hepatitis B , positive test Hepatitis B surface antigen , history Hepatitis C , positive test Hepatitis C antibody , history HIV infection demonstration HIV antibody . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen condition know interfere absorption , distribution , metabolism excretion drug . Any history drug abuse alcohol abuse per DSMIV criterion within 6 month study drug administration . Current treatment hormone replacement therapy within previous 12 month , treatment drug interfere metabolism Testosterone within 30 day study drug administration and/or prescription medication . Difficulty abstain OTC medication duration study . Use oral , transdermal implant contraceptive within 30 day prior drug administration depot contraceptives injection within one year prior drug administration . Evidence pregnancy lactation . Subjects breast feed breast fed within last six ( 6 ) month prior Screening Visit . Administration another investigational drug within 30 day prior study medication administration . Blood donation within 56 day prior study medication administration . Any participation plasma donor plasmapheresis program within seven day precede screen study . Intolerance venipuncture . History abnormal bleeding tendency thrombophlebitis unrelated venipuncture intravenous cannulation . History Deep Venous Thrombosis coagulation disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>testosterone</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>